Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.

Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA; Veterans Aging Cohort Study Team..

Alcohol Clin Exp Res. 2012 Feb;36(2):318-24. doi: 10.1111/j.1530-0277.2011.01601.x. Epub 2011 Jul 28.


An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.

Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA.

J Subst Abuse Treat. 2014 Jul;47(1):35-40. doi: 10.1016/j.jsat.2014.02.008. Epub 2014 Mar 12.


Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.

Mitchell MC, Memisoglu A, Silverman BL.

J Stud Alcohol Drugs. 2012 Nov;73(6):991-7.


Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.

Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group..

J Hepatol. 2014 Jan;60(1):46-53. doi: 10.1016/j.jhep.2013.08.014. Epub 2013 Aug 24.


Study of hepatotoxicity of naltrexone in the treatment of alcoholism.

Yen MH, Ko HC, Tang FI, Lu RB, Hong JS.

Alcohol. 2006 Feb;38(2):117-20.


Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group..

Drug Saf. 2007;30(12):1161-9.


Liver enzymes elevation after HAART in HIV-HCV co-infection.

Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L, Schiff E.

J Viral Hepat. 2005 Jul;12(4):429-34.


Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.

Cooper CL, Breau C, Laroche A, Lee C, Garber G.

HIV Med. 2006 Jan;7(1):32-7.


Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.

Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA; BHIVES Collaborative..

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S62-7. doi: 10.1097/QAI.0b013e31820a820f.


Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.

Clin Infect Dis. 2005 Oct 15;41(8):1186-95. Epub 2005 Sep 13.


A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S21-33.


Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.

Peters PJ, Stringer J, McConnell MS, Kiarie J, Ratanasuwan W, Intalapaporn P, Potter D, Mutsotso W, Zulu I, Borkowf CB, Bolu O, Brooks JT, Weidle PJ.

HIV Med. 2010 Nov;11(10):650-60. doi: 10.1111/j.1468-1293.2010.00873.x.


Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.

Otegbayo JA, Kuti MA, Ogunbode O, Irabor AE, Adewoles IF.

Afr J Med Med Sci. 2012 Dec;41(4):417-22.


Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women.

Dusingize JC, Hoover DR, Shi Q, Mutimura E, Rudakemwa E, Ndacyayisenga V, Gakindi L, Mulvihill M, Sinayobye JD, Musabeyezu E, Anastos K.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):723-30. doi: 10.1089/AID.2014.0170. Epub 2015 May 21.


Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM.

AIDS. 2000 Dec 22;14(18):2895-902.


Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.

French AL, Benning L, Anastos K, Augenbraun M, Nowicki M, Sathasivam K, Terrault NA.

Clin Infect Dis. 2004 Aug 1;39(3):402-10. Epub 2004 Jul 12.


Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G; EPOKA-MASTER Study Group..

BMC Infect Dis. 2005 Jul 14;5:58.


HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R; BHIVES Collaborative..

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S22-32. doi: 10.1097/QAI.0b013e318209751e.

Supplemental Content

Support Center